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Background: Inﬂuenza vaccinations are currently advo-
cated only for individuals over age 50. However, vacci-
nation of all working-age people may be warranted based
on reduced absenteeism from work.
Objective: This study aims to quantify the association
between lost workdays and inﬂuenza, controlling for
other factors. A secondary aim of the study is to assess
the net beneﬁt of expanded vaccination in a workplace
setting.
Research design: Multivariate regression analyses of the
1996 Medical Expenditure Panel Survey Household
Component are used to estimate the number of workdays
missed because of inﬂuenza-like illness (ILI) when con-
trolling for other health, demographic, and employment
factors. Mean productivity costs are measured in terms
of absences from work and valued in dollar terms. The
net beneﬁt of inﬂuenza vaccination is estimated using a
simple decision analysis.
Subjects and measures: Health, demographic, and
employment data for employed individuals between the
ages of 22 and 64 years are analyzed.
Results: The average number of workdays missed due to
ILI was 1.30 days, and the average work loss was valued
at $137 per person. The vaccine strategy was not pre-
ferred in the baseline analysis; however, this result was
sensitive to assumptions regarding the incidence of
inﬂuenza, the cost of delivering the vaccine, and the pro-
ductivity impact of worker absenteeism. Moreover, non-
productivity beneﬁts of vaccination were omitted.
Conclusions: The economic attractiveness of expanded
investment in inﬂuenza vaccination hinges on employer-
and population-speciﬁc assumptions. Our analysis 
provides a simple framework within which competing
considerations of disease epidemiology, worker produc-
tivity, and economic cost may be weighed.
Keywords: absenteeism, inﬂuenza, MEPS, productivity
costs.
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ABSTRACT
Introduction
Inﬂuenza epidemics occur nearly every year from
the late fall through the early spring. In the United
States, the disease causes an average of approxi-
mately 110,000 hospitalizations and 20,000 deaths
per year and imposes a signiﬁcant economic burden
[1]. Treatment and hospitalization occur frequently
in high-risk populations, including people 65 years
or older and those of any age with underlying
chronic respiratory, cardiovascular, metabolic, or
renal diseases [2]. Even for healthy adults, the
typical symptoms of inﬂuenza can restrict daily
activities. Kavet [3], in 1977, estimated that the
costs of work loss due to inﬂuenza ranged from
$0.5 to $2.0 billion, using epidemic models for
which the incidence of inﬂuenza was assumed to
range from 11% to 26%.
The cost-effectiveness of inﬂuenza vaccination
for elderly and other high-risk populations is well
established [4]. Indeed, the Advisory Committee on
Immunization Practices has recommended annual
vaccination against inﬂuenza for individuals older
than 50 years and all adults and children with
chronic medical conditions [1]. However, whether
vaccination is cost-beneﬁcial for the working-age
population has not been determined. While recent
studies show that vaccination programs reduce
health costs in large corporate settings [5–9], the
generalizability of these ﬁndings to all working-age
individuals is not clear. Nichol [10] conducted a
cost-beneﬁt analysis of vaccination using a Monte
Carlo decision model to adjust for demographic
characteristics, year-to-year variability, and vaccine
efﬁcacy rates. However, this analysis still relied
upon the corporate study results cited above for its
base-case estimates of worker absenteeism (base
case: 2 days; range: 0.75–4 days).
The present study is motivated by the hypothe-
sis that there are potential societal gains to be
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enjoyed from greater investment in the vaccination
of employed, working-age individuals. To that end,
we aim to estimate the economic costs of inﬂuenza-
related absenteeism from work using nationally 
representative samples and to compare these to the
estimated costs of increased vaccination. Such infor-
mation could help to support revision of current
guidelines to include working-age individuals. It
could also help both employers and employees 
to identify the degree to which they would beneﬁt
from worker vaccination and the extent to which
they might be willing to bear a share of any new
vaccination program implementation costs.
Data
Source
The data for this study were taken from the 1996
Medical Expenditure Panel Survey (MEPS). The
MEPS is a nationally representative survey of
medical care use and expenditures conducted by 
the Agency for Healthcare Research and Quality
(AHRQ) [11]. The Household Component (HC) of
the MEPS includes detailed data on demographic
characteristics, health conditions, health status, use
of medical care services, charges and payments,
access to care, health insurance coverage, income,
and employment. The MEPS sample was drawn
from respondents to the National Health Interview
Survey. Data were collected via a preliminary
contact followed by a series of six rounds of inter-
views over a 2.5-year period. The public use data
ﬁles of the MEPS are available on the Internet at the
AHRQ home page (http://www.meps.ahrq.gov [last
accessed on May 10, 2002]).
The present study used the following data ﬁles:
1) Medical Conditions (HC-006); and 2) 1996 Full
Year Consolidated Data File (HC-012). Based on
US inﬂuenza surveillance data, widespread
inﬂuenza activity during the 1995–96 seasons
started the week ending November 25 and lasted
until the week ending March 16 [12]. To enhance
the likelihood that we would capture only
inﬂuenza-related workdays missed, we used survey
data collected only during round 1 of the MEPS
follow-up interviews from January 1, 1996, to the
next ﬁeld interviews conducted from March
through July 1996.
Study Sample
The study sample includes all working, non-self-
employed people between the ages of 22 and 64
years. Self-employed individuals were excluded
from the analysis because job beneﬁts such as paid
sick leave were not speciﬁed for these individuals.
The HC-012 contains records of 21,750 eligible
individuals in Round 1. The data of 10,156 people
were excluded because they were either younger
than 22 years or older than 65 years during the
interview period. The data of 4368 persons were
also excluded because they were either self-
employed or not employed. Of the 7226 remaining
observations, the data of 189 were excluded
because of missing information about missed work-
days (147 cases) or hourly wage (42 cases). As a
result of these various exclusions, the data of 7037
observations were analyzed for this study.
Study Variables
Work loss. This study restricts attention to the
work- and productivity-related costs of inﬂuenza
and inﬂuenza-related absenteeism. We adopt this
perspective to inform employer and employee 
decisions regarding vaccination. Our analysis is
premised on the assumption that there may be gains
to be enjoyed by both workers and employers from
greater investment in the vaccination of employed,
working-age individuals. We therefore aim to
provide information that could help both workers
and employers to determine whether they might
enhance productivity by funding a vaccination
program.
Costs of inﬂuenza were measured in terms of
absences from work. Loss of life and unemployment
due to long-term disability were not considered for
this analysis because inﬂuenza-related deaths and
hospitalizations are relatively rare in the working-
age population [13]. Moreover, productivity losses
while on the job were not addressed in this analy-
sis because the data related to job performance were
limited in the MEPS. The survey asked subjects 
to specify how many workdays were missed and 
for what health conditions. A continuous variable
(MISSDAYS) indicating how many days an individ-
ual missed from work was created from the sub-
jects’ responses of missed workdays. All variable
names used for this analysis and their descriptions
are listed in Table 1. The descriptive statistics for
this study population are summarized in Table 2.
The average number of health-related missed work-
days was 1.81 days. Average hourly wages were
$14. We obtained a mean value of 39 usual hours
worked per week. However, because data were
incomplete on the number of hours worked per time
period, we used the median value of 40 hours per
week in our analyses.
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Inﬂuenza-like illness (ILI) and other health
conditions. Information about ILI and chronic
conditions that are thought to increase the risks of
inﬂuenza-related hospitalizations and deaths were
taken from the HC-006 using the International
Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation (ICD-9-CM) codes. All individuals
were asked whether they had any health problems.
Individuals who had ILI during Round 1 were iden-
tiﬁed via self-reports (ICD-9-CM, 487). Approxi-
mately 2.5% of the sample reported having ILI in
the reporting period. Other health conditions such
as chronic lung disease, diabetes mellitus, chronic
heart disease, malignancy, chronic renal disease,
and HIV infection were also collected from all sub-
jects’ responses to the question of medical condi-
tions. These are included to control for other
sources of sick days.
Demographics and employment. Demographic
and employment variables were taken from the 
HC-012. For demographic characteristics, a series
of dummy variables indicating age, sex, race,
marital status, family size, and educational back-
ground were created. As for employment charac-
teristics, dummy variables indicating industry type,
occupation type, and the number of people
employed in the subjects’ place of work were
included for this analysis. Because sick pay beneﬁts
may increase days of absence from work, a variable
measuring whether individuals had such beneﬁts
was included. Union membership was also included
Table 1 Variable names and their descriptions
Variable Description
Missed workdays
MISSDAYS The number of missed workdays
Wage and hours worked
HRWG Hourly wage
HOUR Usual hours worked per week 
Health conditions (HEALTH)
FLU Inﬂuenza-like illness (ICD-9-CM code 487)
LUNGDIS Chronic lung disease (ICD-9-CM codes 490–496, 500, 501, 511, 514, and 518)
DIABETES Diabetes mellitus (ICD-9-CM codes 250, 790, and 791)
HEARTDIS Chronic heart disease (ICD-9-CM codes 397, 410–414, 424, 428, 429, and 785)
CHRONIC Other chronic diseases: malignancy (ICD-9-CM codes 140–208), chronic renal disease (ICD-9-CM 
codes 583, 586,V42,V45, and V56), and HIV infections (ICD-9-CM codes 042, 279, and 795)
Demographic characteristics (DEMO)
FAMSIZE Family size
AGE3039 Age 30 to 39 years
AGE4049 Age 40 to 49 years
AGE5059 Age 50 to 59 years
AGE6064 Age 60 to 64 years
FEMALE Sex female
NONWHITE Race nonwhite
MARRIED Being married
EDUNODEG Education no degree
EDUCOLL Education bachelor’s degree
EDUGRAD Education master’s or doctorate degree
EDUOTHRE Education other degree
Employment characteristics (EMP)
SICKPAY Having sick pay beneﬁts
EMPSIZE2 Number of employees 10–24
EMPSIZE3 Number of employees 25–99
EMPSIZE4 Number of employees 100–499
EMPSIZE5 Number of employees 500 or more
INUNION A member of a labor union
INDCONST Employed in construction industry
INDMANUF Employed in manufacturing
INDTRANS Employed in transportation, communications, and utilities
INDSALES Employed in sales
INDFINAN Employed in ﬁnancial, insurance, and real estate industry
INDREPAI Employed in repair services
INDPROFE Employed in professional services
INDOTHER Employed in other industries
OCCPPROF Occupation professional
OCCPMANA Occupation managerial and administrative workers
OCCPBLUE Occupation blue-collar workers
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because greater job security may also increase
absences.
Models and Estimations
Number of Missed Workdays
Information on ILI and other chronic health condi-
tions was collected from all subjects, regardless of
whether or not they were employed during the
survey period. Employed subjects were then asked
to report the number of days missed from work
related to these health conditions. Unfortunately,
there is no direct indicator of how many days lost
are due to a speciﬁc health condition. Thus, we esti-
mate the number of workdays missed due to ILI
controlling for other chronic conditions. We esti-
mate days lost due to ILI as follows:
(1)
where ILI is a dummy variable indicating the pres-
ence of ILI, HEALTH is a vector of variables indi-
cating an individual’s health conditions, DEMO 
is a vector of variables describing demographic 
characteristics, EMP is a vector of variables describ-
ing employment characteristics, and e is an error
term.
The dependent variable, missed workdays, did
not satisfy the basic OLS normality assumption
[14]. The distribution was skewed with two-thirds
of the sample having no day missed, approximately
24% of the sample with 1–3 days missed, and
0.06% of the sample with more than 100 days
missed. We therefore used the negative binomial
MISSDAYS
ILI,  HEALTH, DEMO, EMP
=
( ) +f e,
Table 2 Sample (N = 7037) descriptive statistics
Variable Mean SD Minimum Maximum
Missed workdays* 1.81 7.36 0 180
Hourly wage 14.09 31.00 0.03 2125
Usual hours worked per week† 39.01 9.54 1 168
ILI 0.03 0.16 0 1
Chronic lung disease 0.04 0.20 0 1
Diabetes mellitus 0.02 0.15 0 1
Chronic heart disease 0.01 0.12 0 1
Other chronic diseases 0.01 0.10 0 1
Family size 3.08 1.52 1 14
Age (years)
30 to 39 0.33 0.47 0 1
40 to 49 0.28 0.45 0 1
50 to 59 0.14 0.35 0 1
60 to 64 0.03 0.18 0 1
Sex female 0.50 0.50 0 1
Race nonwhite 0.17 0.38 0 1
Being married 0.69 0.46 0 1
Education
No degree 0.18 0.38 0 1
Bachelor’s degree 0.19 0.39 0 1
Master’s or doctorate degree 0.08 0.26 0 1
Other degree 0.08 0.28 0 1
Having sick pay beneﬁts 0.65 0.48 0 1
Number of employees
10–24 0.15 0.35 0 1
25–99 0.26 0.44 0 1
100–499 0.24 0.42 0 1
500 or more 0.17 0.38 0 1
A member of a labor union 0.16 0.36 0 1
Construction industry 0.04 0.20 0 1
Manufacturing 0.19 0.40 0 1
Transportation, communications, and utilities 0.07 0.26 0 1
Sales 0.17 0.37 0 1
Financial, insurance, and real estate industry 0.07 0.25 0 1
Repair services 0.06 0.24 0 1
Professional services 0.26 0.44 0 1
Other industries 0.11 0.32 0 1
Professional 0.19 0.39 0 1
Managerial and administrative workers 0.14 0.35 0 1
Blue-collar workers 0.28 0.45 0 1
*The distribution of the “missed workdays” variable has point mass of 66% on the value 0, 24% on values between 1 and 3, and all but 0.06% of the remainder
between 4 and 99.This suggests a high degree of positive skewness and explains our choice of the NB regression model.
†Because the number of hours worked per time period was not available in 126 samples, a value of 40 hours per week was assumed as median value of the study
samples.
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(NB) regression instead, because it is often more
appropriate to analyze non-negative, left-skewed
count data. The NB model is an extension of the
Poisson model and adds an extra parameter to
permit the mean to differ from the variance, as it
does in this case [15]. All statistical analyses were
conducted using STATA version 6.0 (Stata Corpo-
ration, College Station, TX).
Our aim was to calculate the incremental number
of workdays missed due to ILI, holding all else con-
stant. In the NB model, calculating the partial deriv-
ative of the impact of the change in ILI on days
missed is more complicated than it would be for
OLS. We calculated the incremental effect of ILI on
the number of workdays missed (Ddays) using the
following the method: We ﬁrst assumed all individ-
uals suffered from ILI (i.e., set ILI = 1) and then esti-
mated the number of workdays lost under these
conditions ( ). We then supposed that no individ-
uals suffered from ILI (set ILI = 0) and 
estimated the lost workdays ( ) attributable to
each individual. Comparing these two ﬁndings
yielded an estimate of the impact of ILI on work
loss days:
(2)
Costs of Absenteeism
Costs of lost workdays were calculated by multi-
plying the estimated number of workdays missed by
the daily wage attributable to each individual. The
availability of individual-speciﬁc hourly wages and
usual hours worked per week is an advantage over
previous studies [16]. However, because ILI is
reported in days lost, we converted data on hours
worked per week and hourly wage rates to income
per week. To obtain a daily rate, we divided by days
worked. Unfortunately, we did not have data on 
the number of days worked. Instead, we assumed
that all individuals worked 5 days per week. This
seems to be a good estimate because approximately
85% of the sample reported that they usually
worked between 30 and 50 hours per week.
Using this method we calculated an estimate of
the mean productivity costs (MPC) associated with
inﬂuenza:
(3)
where Ddaysi is the estimated number of days lost
due to ILI, wagei indicates the hourly wage ($/hr),
hri indicates usual working hours per week, and n
indicates the number in the sample.
MPC days
hr wage
= ¥
¥
=( )
Â1 5
1 2
n
i n
i
i iD
, , . . . ,
Ddaysi Ai Bi Ai Biy y x x
i n
= ( ) - ( ) = ( ) - ( )
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Decision Analysis for Evaluating Net Beneﬁt 
of Vaccination
The net beneﬁt of vaccination cannot be evaluated
simply by comparing the cost of ILI with the cost
of vaccination. The comparison must be made
between total expected costs with and without the
vaccine, taking into account the incidence of infec-
tion and both the costs and the efﬁcacy of vaccina-
tion. We developed a simple decision model to
evaluate the net beneﬁts, as shown in Fig. 1. The
decision is simply to vaccinate or not. The incidence
of ILI is given by variable i. The efﬁcacy of the
vaccine (measured as a percent reduction in the inci-
dence of infection) is given by variable e. Thus, the
incidence of ILI for those who are vaccinated is (1
– e)i. The per-person cost of vaccination is CV. The
value of all wages forgone (which we use as a proxy
for the costs of getting the ﬂu) is CF. We acknowl-
edge that this is an underestimate of the true cost
and consider adjustments to this in our discussion
of sensitivity analysis, below. Averaging out gives us
the expected cost of the “vaccine” strategy,
(4)
and the expected cost of the “no-vaccine” strategy,
(5)
A simple decision rule would be to vaccinate when-
ever the expected cost of doing so is less than the
expected cost of failing to vaccinate, a condition
given by the following expression:
(6)
Results
Estimation of the Number of Missed Workdays
Table 3 presents the regression coefﬁcients of missed
workdays. The NB model indicates a greater
number of workdays missed for people who had
C C e i C i C C ieV F F V F+ -( ) > * ﬁ <1 .
C iF * .
C C e IV F+ -( )1 ,
Decision
(1-e)i
Vaccine
1-(1-e)i No ﬂu
i
No vaccine 
(1-i) No ﬂu
Flu cost (CF) + 
vaccine cost (CV) 
Vaccine cost (CV)
Flu cost (CF)
No cost 
ﬂu 
ﬂu
Figure 1 Decision tree for net beneﬁt to vaccination.
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health conditions other than diabetes, were 30 years
or older, were female, had sick pay beneﬁts, worked
at a large company, were union members, or were
blue-collar workers. Those who were married or
had college or higher degrees missed fewer days of
work.
From the NB model, the incremental effect of ILI
on the number of days missed was calculated using
the equation ( ) – ( ), as described previously.
The results suggested that an individual who had
ILI missed 1.30 days more compared to one who
did not have ILI. We interacted the impact of ILI
and chronic conditions; however, there were no sig-
niﬁcant interaction effects to report here.
Costs of Absenteeism
Mean absenteeism costs because of ILI are esti-
mated to be $137 per person in 1996 dollars.
yˆBiyˆAi
Net Beneﬁt to Vaccination
To calculate the net beneﬁts to vaccination, we start
with baseline values. We then use alternative values
to determine how sensitive the conclusions are to
the initial values.
Baseline Analysis
We set the following values for the baseline analy-
sis: CV = $16.70; CF = $137; i = 2.5%; and e = 80%.
We use the inﬂuenza prevalence rate reported in the
MEPS as our baseline incidence estimate (i). As our
proxy for the cost of inﬂuenza (CF), we use our 
calculation for lost wages. We use a value of 80%
for the vaccine efﬁcacy (e) based on the information
that the vaccine is estimated to be between 70 and
90% effective in preventing illness of healthy
persons younger than 65 years when there is a good
match between the vaccine and the circulating
viruses [17]. As for the cost of delivering the vaccine,
we use the value reported by Nichols [10] that
includes direct and indirect medical costs as well as
costs of potential side effects. Thus, our vaccine
delivery cost includes both direct and indirect com-
ponents, while our measure of the savings to be
enjoyed by averting a case of inﬂuenza includes only
indirect effects. Given that our purpose is to portray
the net value of vaccination, this represents a con-
servative approach. Using these baseline numbers,
we estimate that CV/CF = $16.70/$137 = 0.1219 and
ie = 0.025 ¥ 0.80 = 0.020, suggesting that the
expected cost of the decision to vaccinate exceeds
the expected cost of not vaccinating.
One-Way Sensitivity Analysis
Speciﬁc parameter values will vary across both
employers and worker populations. Employee age,
sex, education, socioeconomic status, and other
variables may all greatly inﬂuence rates of inﬂuenza
incidence. The probability of ﬂu-associated hospi-
talizations and outpatient visits, which are impor-
tant cost outcomes, would be substantially higher
in persons with chronic conditions than among
healthy persons. Moreover, the incidence of
inﬂuenza varies yearly, making it difﬁcult to
compare across years and thus across studies [18].
In a study conducted more than 20 years ago, the
incidence was approximately 5 to 10 times higher
than that observed in our study [3]. A review by
Bridges et al. [6] reported that inﬂuenza incidence
varied between 1 and 26% among people aged 18
to 64 years depending on inﬂuenza seasons and 
the demographic characteristics of the study 
populations.
We adopted a conservatively low 2.5% incidence
Table 3 Regression analysis predicting the number of
missed workdays
NB model
Variable Coefﬁcient SE
ILI 0.535† 0.192
Chronic lung disease 0.834† 0.150
Diabetes mellitus –0.033 0.212
Chronic heart disease 1.286† 0.256
Other chronic diseases 1.428† 0.302
Family size –0.005 0.022
Age (years)
30 to 39 0.305† 0.086
40 to 49 0.230* 0.092
50 to 59 0.379† 0.109
60 to 64 0.988† 0.195
Sex female 0.490† 0.069
Race nonwhite –0.042 0.083
Being married –0.260† 0.074
Education
No degree 0.076 0.091
Bachelor’s degree –0.195* 0.098
Master’s or doctorate degree –0.434† 0.145
Other degree –0.062 0.117
Having sick pay beneﬁts 0.204† 0.074
Number of employees
10–24 –0.160 0.111
25–99 0.160 0.097
100–499 0.308† 0.104
500 or more 0.548† 0.111
A member of a labor union 0.231* 0.090
Construction industry 0.154 0.258
Manufacturing –0.108 0.225
Transportation, communications, and utilities 0.136 0.241
Sales 0.220 0.230
Financial, insurance, and real estate industry –0.163 0.255
Repair services 0.152 0.249
Professional services 0.179 0.230
Other industries 0.089 0.238
Professional –0.176 0.106
Managerial and administrative workers –0.163 0.107
Blue-collar workers 0.360† 0.097
Intercept –0.348 0.256
*Signiﬁcant at P < .05.
†Signiﬁcant at P < .01.
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value for our baseline assumption. The one-way
sensitivity analysis depicted in Fig. 2, however, con-
siders the impact of alternative incidence assump-
tions on the optimal decision. We hold variables CV,
CF, and e at their baseline values and consider the
changes in incidence variable, i ranging from 0% to
25%. When i = 0, there is no inﬂuenza and (not sur-
prisingly) the expected cost of the no-vaccine strat-
egy is $0; the expected cost of the vaccine strategy
is simply the cost of the vaccine itself ($16.70).
Rising incidence levels cause the expected costs of
both strategies to rise; however, the cost of the no-
vaccine strategy rises more steeply. At an incidence
level of 15.2%, the two strategies have equal
expected costs, suggesting that this is the popula-
tion incidence level at which a cost-minimizing 
decision maker would be indifferent between 
vaccinating and not vaccinating, given our 
assumptions.
The 15.2% incidence threshold will vary,
depending on what is assumed about the efﬁcacy 
of vaccination. Our baseline efﬁcacy assumption of
80% is the ﬁgure cited in the literature for vaccines
against serologically conﬁrmed inﬂuenza illness in
healthy persons. However, actual vaccine efﬁcacy
against ILI may be substantially lower for a number
of reasons. First, the inﬂuenza vaccine does not
protect against ﬂu-like illnesses; Demicheli and
coworkers [19], for example, have obtained esti-
mates of vaccine efﬁcacy as low as 24% in studies
where the diagnosis of inﬂuenza was based on clin-
ical ﬁndings but not conﬁrmed serologically.
Second, vaccine efﬁcacy may be lower for persons
with chronic conditions. Vaccine efﬁcacies ranging
from 30% to 60% have been reported among
elderly patients [20–22]. Finally, poor matches
between the vaccine and circulating viruses are
always a concern. Not surprisingly, the vaccine
strategy’s attractiveness is reduced when a lower
vaccine efﬁcacy is assumed. By way of illustration,
if we assume the vaccine efﬁcacy to be 50% rather
than 80%, the incidence threshold that leaves deci-
sion makers indifferent between vaccinating and
not vaccinating would rise from 15.2% to 24.4%.
Further reducing the vaccine efﬁcacy to the value of
24% reported by Demicheli et al. [19] produces an
incidence threshold of 50.8%.
Similar threshold points of indifference (holding
all other variables at their baseline values) can be
obtained for each of the other parameters in this
analysis. For example, the threshold cost of the
vaccine is CV = $2.74. This suggests that an
employer who can take advantage of scale or other
economies to drive the costs of the vaccine below
$2.74 may, all other things being equal, ﬁnd it
attractive to vaccinate employees. The threshold
per-case cost of inﬂuenza is CF = $835. Employers
who assign high values to lost productivity due to
worker absenteeism can use this ﬁgure as a basis by
which to measure the value of vaccinating their
employees. Employees who wish to consider factors
other than the value of lost wages, such as any pain
and suffering, lost leisure, or likelihood of spread-
ing the ﬂu to their family, may use a much higher
ﬁgure as their expected losses and may ﬁnd the
vaccine to be cost-beneﬁcial. In an employee’s
private decision to get vaccinated, the cost of the
vaccine may be zero because of either health 
insurance coverage or direct provision by the
employer.
The following combination of parameter values
represents a plausible scenario that portrays the
decision to vaccinate in a favorable light: CV =
$8.35 (half of baseline); CF = $274 (double base-
line); i = 5.0% (double baseline); and e = 80%.
Using these numbers, CV/CF = 0.0305 and ie =
0.0400 and, hence, the vaccine strategy is preferred.
Discussion
Net Beneﬁt to Vaccination
This study demonstrates that ILI accounts for mil-
lions of days lost from work and causes substantial
economic losses to employers via lost productivity.
Although our baseline analysis would appear not 
to favor vaccination as an economically attractive
option, this ﬁnding is highly sensitive to employer-
and population-speciﬁc parameter values and
includes only some of the relevant beneﬁts. Even
small reductions in the cost of delivering the vaccine
and/or plausible increases in the incidence of infec-
tion, the cost per case, or the beneﬁts of vaccination
could reverse our conclusion. For example, there
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Figure 2 Sensitivity analysis: impact of incidence. () No vaccine;
() vaccine.
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may be ways of reducing the marginal cost of
administering the vaccine. These would include
delivering the vaccine at the time of a medical visit
for another purpose, using a work site location to
administer vaccines thus reducing time costs [10],
and taking advantage of economies of scale and/or
lowering overhead by having a “vaccine day” at
work. Furthermore, our incidence rate, 2.5%, may
be at the low end of the range—partly because our
study focused on only one inﬂuenza season (limited
data collected from January through June 1996)
and possibly because we selected a healthier study
population (namely, employed individuals aged
22–64 years). In addition, some individuals in our
sample may have received the inﬂuenza vaccine,
which would again have the effect of biasing 
our estimates of the beneﬁts in a conservative 
direction.
Underestimates of ILI Costs
Our estimated cost of ILI to the individual would
likely underreport the true costs because of the fol-
lowing reasons: First, days lost from work capture
only some of the costs of ILI that could be averted.
Other costs include reductions in home productiv-
ity, loss of leisure, pain and suffering, and the pos-
sibility of spreading the contagious disease to others
at home and at work. Second, the costs of physi-
cian visit as well as prescription and over-the-
counter medications for treatment of inﬂuenza
symptoms are not included. Finally, because our 
calculations include the Christmas and New Year’s
holiday season, we may not capture some workdays
lost because of preplanned vacations.
Limitations of the Research Design
Despite the advantages of using data from a nation-
ally representative survey, our study design entails
several limitations and our ﬁndings must be inter-
preted with caution. One limitation is that the data
on health conditions in the MEPS are poorly deﬁned
and based on self-reported—rather than clinically
veriﬁed—information. There are no clinically veri-
ﬁed data on inﬂuenza in a large, population-based
sample. Even if such data were available, however,
it is not clear how useful they would be in light of
the fact that not everyone sees a physician when
they suffer from inﬂuenza. Further, because of inter-
actions with chronic diseases, attribution to ﬂu
alone may be difﬁcult. The risk with self-reported
data is that some people may be unable to discern
whether they had inﬂuenza or other respiratory
illness. Thus, the impact of inﬂuenza on absen-
teeism might be either underestimated or overesti-
mated. We have tried to adhere to previously 
published practice, in this regard. Mauskopf and
colleagues [23], for example, developed a pharma-
coeconomic model of inﬂuenza treatment that
assumed an equal number of days to alleviate major
symptoms in both inﬂuenza-positive and ILI
patients. Moreover, broad case deﬁnitions of
inﬂuenza have been used in several inﬂuenza vacci-
nation studies [5,7]. For example, the US Inﬂuenza
Surveillance System deﬁnes ILI as fever (tempera-
ture of >100°F) plus either a cough or a sore throat
[12]. Therefore, even though the proportion of ILI
that is attributable to inﬂuenza versus other condi-
tions with similar symptoms could vary from year
to year, our estimate of missed workdays due to ILI,
based on 1996 MEPS data, may be generalizable to
other settings.
Our estimate of inﬂuenza-related workdays
missed is smaller than those reported by most other
studies. For example, a study conducted in a large
pharmaceutical company in the UK reported a
mean of 2.8 workdays missed because of inﬂuenza-
like symptoms [8]. Another study conducted in 
six Kayser-Roth textile plants in North Carolina
reported that participants who had at least one
event of ILI lost an average of 1.5 workdays [7].
Possible explanations for these differences in the
impact of inﬂuenza on absenteeism might have to
do with employment characteristics, the severity of
the ﬂu season, and the percentage vaccinated. Most
previous studies evaluated samples drawn from
large companies with generous sick leave beneﬁts,
which may result in more days absent. One excep-
tion is the study conducted among Ford Motor
Company employees, which reported only 0.8 days
absent per episode of ILI [6]. But, 35% of our study
sample had no sick beneﬁts. Therefore, our ﬁndings
might be more generalizable to the civilian, nonin-
stitutionalized population in the United States than
studies of only workers in large corporations. The
discrepancy may also occur because of differences
in control variables; we controlled for other health
problems that may result in work loss days. Failing
to control for other health effects may falsely
attribute extra days lost to ILI.
Conclusion
The economic attractiveness of investing in
inﬂuenza vaccine depends greatly upon the costs of
vaccine, the costs of lost time, and the incidence 
of inﬂuenza in a speciﬁc population. The simple
decision rule we have developed could be useful 
to decision makers in weighing these competing
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considerations and tailoring the vaccine decision to
the characteristics of speciﬁc employers and at-risk
employee populations.
Portions of this paper are based on research conducted
by M.A. for his Master of Public Health thesis at the
Department of Epidemiology and Public Health, Yale
School of Medicine, New Haven, CT.
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